ABSTRACT OBJECTIVES This study sought to investigate the efficacy of prasugrel compared with clopidogrel in clopidogrel nonresponders.
Valenti et al.
prasugrel compared with clopidogrel nonresponders of the RECLOSE-2-ACS study. According to this hy- 
RESULTS
We screened 1,550 patients after administering a 600-mg loading dose of clopidogrel. Of these, 302
patients had a residual platelet reactivity >70% on the ADP test and were switched to prasugrel treatment. This patient cohort was compared with that of the RECLOSE-2-ACS study that included 248 clopidogrel nonresponders ( Figure 1 ). Table 1 summarizes the baseline clinical characteristics of the 2 groups.
Nonresponders in the RECLOSE-3 had a higher incidence of hypertension, a history of MI, a history of RECLOSE ¼ Responsiveness to CLOpidogrel and StEnt Thrombosis. were prescribed aspirin and proton pump inhibitors less frequently than the RECLOSE-2-ACS patients. Valenti et al.
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At 1 year, 91% and 88% of the patients in the RECLOSE-2-ACS and RECLOSE-3, respectively, were receiving thienopyridine treatment, and the number of patients had decreased to 68% and 21%, respectively, at 2-year follow-up.
The 2-year cardiac mortality rate was 4.0% in the RECLOSE-3 group and 9.7% in the RECLOSE-2-ACS group (p ¼ 0.007). The difference in 2-year cardiac mortality remained considering exclusively patients with ACS on admission who accounted for the major difference in baseline characteristics between groups: 3.2% and 9.7%, respectively (p ¼ 0.023) ( Table 3 There were no differences in major bleeding rates, whereas the minor bleeding rate was higher in the RECLOSE-3 group (Table 3) .
DISCUSSION
The main finding of the RECLOSE-3 study is that nonresponsiveness to clopidogrel is a modifiable risk factor for cardiac death after PCI. The RECLOSE-3
shows that clopidogrel nonresponders switching to prasugrel treatment is associated with a 2-year cardiac mortality rate nearly identical to the population of clopidogrel responders in the RECLOSE-2-ACS: 4% and 4.3%, respectively. Moreover, the rates of definite or probable stent thrombosis were lower in the RECLOSE-3 group than in the RECLOSE-2-ACS group (0.7% and 4.4%, respectively, p ¼ 0.004). 
WHAT IS NEXT?
The results of this study should be considered for further studies of tailored therapy using new antithrombotic agents. Clopidogrel Nonresponders
